2022
DOI: 10.3389/fimmu.2022.870216
|View full text |Cite
|
Sign up to set email alerts
|

Therapy Targets SARS-CoV-2 Infection-Induced Cell Death

Abstract: Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV-2 has become a global health issue. The clinical presentation of COVID-19 is highly variable, ranging from asymptomatic and mild disease to severe. However, the mechanisms for the high mortality induced by SARS-CoV-2 infection are still not well understood. Recent studies have indicated that the cytokine storm might play an essential role in the disease progression in patients with COVID-19, which is characterized by the uncontrolled release of cytokines a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
11
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(11 citation statements)
references
References 130 publications
(111 reference statements)
0
11
0
Order By: Relevance
“…Moreover, immunosuppressive therapy, such as the corticosteroids used alone in our patients, has been used in subjects with mild/severe COVID-19 to diminish and control hyperinflammation and CSS [ 6 , 32 ]; however, their principal diseases (i.e., uncontrolled T2DM/hypertension) worsened these infectious health conditions, favoring the proliferation of infectious pathogens and causing major damage. SARS-CoV-2 induces cellular death of pneumocytes by pyroptosis and apoptosis in endothelial cells [ 33 ], thickening of the alveolar wall, and worsening of hypoxia. In addition, uncontrolled intracellular proliferation of Mtb by failure of the IFN-γ IL-12/IL-23 axis and TNFα reduces acidification of lysosomes with less destruction of Mtb.…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, immunosuppressive therapy, such as the corticosteroids used alone in our patients, has been used in subjects with mild/severe COVID-19 to diminish and control hyperinflammation and CSS [ 6 , 32 ]; however, their principal diseases (i.e., uncontrolled T2DM/hypertension) worsened these infectious health conditions, favoring the proliferation of infectious pathogens and causing major damage. SARS-CoV-2 induces cellular death of pneumocytes by pyroptosis and apoptosis in endothelial cells [ 33 ], thickening of the alveolar wall, and worsening of hypoxia. In addition, uncontrolled intracellular proliferation of Mtb by failure of the IFN-γ IL-12/IL-23 axis and TNFα reduces acidification of lysosomes with less destruction of Mtb.…”
Section: Discussionmentioning
confidence: 99%
“…This can take place in immune cells and is also reported to occur in keratinocytes and some epithelial cells. As a consequence of pyroptosis, the release of proinflammatory cytokines is triggered in COVID-19 patients, which possibly affects macrophage and lymphocyte functions [ 110 , 111 , 112 , 113 , 114 , 115 ]. This is, perhaps, responsible for peripheral lymphopenia in severe COVID-19 patients.…”
Section: Possible Mechanisms Underlying Failure Of Containing Sars-co...mentioning
confidence: 99%
“…This is, perhaps, responsible for peripheral lymphopenia in severe COVID-19 patients. The role of inflammasome is also related to development of severe inflammation in COVID-19 patients [ 111 , 112 , 113 , 114 , 115 , 116 ]. In addition to this, attention should be focused on the initial failure or suboptimal induction of innate immunity in the host during initial exposure to SARS-CoV-2 in order to allow for the development of proper insights into the cellular and molecular mechanisms underlying severe COVID-19.…”
Section: Possible Mechanisms Underlying Failure Of Containing Sars-co...mentioning
confidence: 99%
“… 50 Several proteins, including Mpro, 3CLpro, and PLpro, are essential for the viral infection cycle and replication. In addition, the envelope protein can form cation channels, inducing host cell death in vitro and a cytokine storm in vivo 71 (Figure 1 ). Moreover, some effective therapeutic, United States Food and Drug Administration (US FDA)‐approved agents with a well‐established safety profile have been identified to combat this viral disease with activity against key proteins.…”
Section: Potential Pathogenic Targets Of Sars‐cov‐2 For Antiviral The...mentioning
confidence: 99%